← Leaderboards
Marjorie G. Zauderer
Sloan-Kettering Inst Can Research
$2,538,334
Attributed
$5,076,667
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2016–23$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,076,667 · 2
By mechanism
R01$5,076,667 · 2
Top collaborators
- Prasad S. Adusumilli5 shared
- Filippo G Giancotti5 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Prasad S. Adusumilli$7,809,681
- Stephen Barnett Solomon$1,149,224
- Govindarajan Srimathveeravalli$2,024,698
- James A Fagin$27,970,638
- Luis F Parada$23,930,635
Others in their field
Top investigators on “Binding”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Barton F Haynes · Duke University$280,359,422
- David Heimbrook · Leidos Biomedical Research, Inc.$116,636,515
- Michael P Snyder · Yale University$97,195,243
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
Research focus
BindingImproved OutcomePathway InteractionsSafetyPleuralMalignant NeoplasmsMediatingNeoplastic CellTumorSamplingPleural CavityPhase I TrialClinical TrialsPatient-Focused OutcomesAutologousCd4 Positive T LymphocytesAdoptive TransferCd19 GeneCar T Cell TherapyAnti-Pd-1ExhaustionChimeric Antigen ReceptorChimeric Antigen Receptor T CellsAntigen Targeting
Grant awards (10)
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$712,796
R01 · FY2023 · CA
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$712,796
R01 · FY2022 · CA
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$1
R01 · FY2021 · CA
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$727,344
R01 · FY2020 · CA
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$182,854
R01 · FY2020 · CA
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$727,344
R01 · FY2019 · CA
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$481,115
R01 · FY2019 · CA
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$495,996
R01 · FY2018 · CA
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$510,996
R01 · FY2017 · CA
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$525,425
R01 · FY2016 · CA